Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma-A multicenter real-world experience in Israel.

BACKGROUND: Merkel cell carcinoma (MCC) is a rare and aggressive malignancy of the skin, affecting predominantly the fair-skinned older population exposed to high levels of ultraviolet light. Immune suppression is considered a significant risk factor. With the recent advances in the field of immunotherapy, the treatment paradigm for advanced MCC, traditionally based on chemotherapy, has largely shifted to anti-PD-L1 and PD-1 agents such as avelumab and pembrolizumab, respectively. However, real-world data remain sparse. The aim of this study was to assess real-world evidence of the effectiveness of avelumab in a diverse group of patients with MCC in Israel. METHODS: The electronic databases of five university hospitals in Israel were searched for all consecutive patients with MCC treated with at least one dose of avelumab in 2018-2022. Data on baseline, disease-related, treatment-related, and outcome parameters were collected and analyzed. RESULTS: The cohort included 62 patients of whom 22% were immune-suppressed. The overall response rate to avelumab was 59%. The median progression-free survival was 8.1 months, and the median overall survival, 23.5 months, with no differences between immune-competent and immune-suppressed patients. Treatment was well tolerated; any-grade toxicity developed in 34% of patients, and grade 3-4 toxicity, in 14%. CONCLUSIONS: Avelumab was found to be effective and safe for the treatment of advanced MCC in a diverse group of patients, including some with immune suppression. Further studies are warranted to evaluate the optimal sequence and duration of treatment and to assess the potential role of avelumab for earlier stages of MCC.

Merkel cell carcinoma in lymph nodes with and without primary origin.

The prognosis of MCC with lymph node involvement was better in patients with an unknown than a known primary. Treatment with a uniform aggressive combined chemoradiation regimen, with or without lymphadenectomy, led to better survival rates than previously reported.

[Blindness and symmetrical neurological deficit in a patient with colon cancer receiving adjuvant chemotherapy: is it always cancer?].

Posterior reversible leukoencephalopathy syndrome [PRES] is characterized by a symmetrical brain edema. It is rarely caused by chemotheraphy. While steroids can lead to deterioration in the condition of a PRES patient, they are still the drug of choice for the more common condition of brain edema secondary to metastases. We describe the case of a colon cancer patient who underwent adjuvant treatment with capecitabine and oxaliplatin and was admitted to the hospital with seizures and brain edema. On admission, the condition was attributed to brain metastases and hence a high dose steroid treatment was initiated. Later on, as the patient became comatose, the CT was revised and PRES was suggested as an alternative diagnosis. After tapering the steroids the patient gradually recovered. This report emphasizes the need to be alert and not to confuse PRES with brain metastasis in cancer patients.